The epitranscriptome of vero cells infected with sars-cov-2 assessed by direct rna sequencing reveals m6a pattern changes and drach motif biases in viral and cellular rnas

HIGHLIGHTS

SUMMARY

In the course of SARS-CoV-2 Pandemic, these cells were vastly used in pre-clinical tests of a wide range of antiviral drug candidates (Agostini et_al, 2019; Schultz et_al, 2022), vaccine candidates (Folegatti et_al, 2020; Ló pez et_al, 2021), serving as a main screening method for selection of best candidates to progress on clinical trials. The gold-standard method to evaluate titles of neutralizing antibodies after COVID-19, or vaccination, use Vero cell as reporter (Sadoff et_al, 2021; Wheatley et_al, 2021), reinforcing the clinical and pharmacological relevance of these cells. The Vero cell . . .

 



If you want to have access to all the content you need to log in!

Thanks :)

Username or Email

Password

Remember me

Lost your password?

If you don't have an account, you can create one here.